MRGPRX1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1161850	1.00	20/20
SCHEMBL1162246	1.00	20/20
SCHEMBL1162417	1.00	20/20
SCHEMBL392042	0.53	15/20
SCHEMBL1808043	0.53	9/20
SCHEMBL850454	0.63	8/20
SCHEMBL851411	0.51	8/20
SCHEMBL871581	0.41	8/20
SCHEMBL1866303	0.41	8/20
SCHEMBL870838	0.40	8/20
SCHEMBL851435	0.82	7/20
SCHEMBL851549	0.65	7/20
SCHEMBL872571	0.41	7/20
SCHEMBL1089805	0.70	6/20
SCHEMBL529361	0.49	6/20
Resatorvid (SCHEMBL871572)	0.43	6/20
Resatorvid (SCHEMBL872197)	0.43	6/20
Resatorvid (SCHEMBL1821271)	0.43	6/20
SCHEMBL871281	0.43	6/20
SCHEMBL871428	0.43	6/20

Clinical trials — most relevant to MRGPRX1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma	PHASE4	COMPLETED
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma	PHASE2	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Investigation the Effect of Montelukast in COVID-19	PHASE2	UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis	PHASE2	COMPLETED
Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)	PHASE1	COMPLETED
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria	PHASE1	RECRUITING
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Unraveling the Pathogenesis of Pruritus in Intrahepatic Cholestasis of Pregnancy	nan	UNKNOWN
Investigation of the Pruritogens of Liver-related Diseases	nan	UNKNOWN
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
Histamine Responsiveness in McCune-Albright Syndrome	nan	COMPLETED
The Severe Asthma Research Program III-Boston Clinical Site	nan	COMPLETED
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Repeat Immunoadsorption Post Covid ME/CFS	nan	COMPLETED
Allergy and Immunology Natural History Study	nan	RECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma	nan	UNKNOWN
Molecular Mechanism of Asthma	nan	WITHDRAWN
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments	nan	RECRUITING
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies	nan	COMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.	nan	RECRUITING
Longitudinal Observational Study of Severe Asthma	nan	COMPLETED
Thrombin Regulated Platelet Activation	nan	COMPLETED
The Real-world Treatment Satisfaction by Gefapixiant in RCC	nan	RECRUITING
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
Cause of Unexplained Anaphylaxis	nan	ACTIVE_NOT_RECRUITING
Clinical Characteristics and Pathophysiology of Post-Traumatic Headache	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MRGPRX1 binder may also engage these)

Protein	Name	Similarity
Q4QXU3	—	1.000	Q4QXU3 →
MRGPRX4	Mas-related G-protein coupled receptor member X4	1.000	landscape →
Q5U9D9	—	0.999	Q5U9D9 →
Q4QXU4	—	0.999	Q4QXU4 →
Q4QXX9	—	0.999	Q4QXX9 →
Q96LB0	—	0.998	Q96LB0 →
Q4QXU5	—	0.998	Q4QXU5 →
Q2LL16	—	0.998	Q2LL16 →
Q4QXU6	—	0.997	Q4QXU6 →
Q4QXU0	—	0.996	Q4QXU0 →
Q4QXU2	—	0.995	Q4QXU2 →
MRGPRX2	Mas-related G-protein coupled receptor member X2	0.995	landscape →
Q7TN45	—	0.994	Q7TN45 →
Q91ZC6	—	0.989	Q91ZC6 →
Q7TN49	—	0.986	Q7TN49 →
Q91WW5	—	0.986	Q91WW5 →
Q91WW4	—	0.980	Q91WW4 →
Q7TN50	—	0.977	Q7TN50 →
Q91ZB9	—	0.977	Q91ZB9 →
Q3UG61	—	0.977	Q3UG61 →
Q91WW3	—	0.976	Q91WW3 →
Q91ZC5	—	0.976	Q91ZC5 →
Q91ZC0	—	0.976	Q91ZC0 →
Q8R4G1	—	0.976	Q8R4G1 →
Q8CIP3	—	0.975	Q8CIP3 →
Q91ZC7	—	0.975	Q91ZC7 →
Q91ZC4	—	0.973	Q91ZC4 →
Q3KNA1	—	0.973	Q3KNA1 →
Q3UG50	—	0.971	Q3UG50 →
Q91WW2	—	0.964	Q91WW2 →